Nexalin Technology, Inc.NXLEarnings & Financial Report
Nexalin Technology, Inc. is a medical technology enterprise that develops and commercializes non-invasive cranial electrotherapy stimulation devices, which help treat mental health conditions including anxiety, depression and insomnia. Its products are mainly sold to healthcare providers and patients in North America and global emerging markets.
NXL Q4 FY2025 Key Financial Metrics
Revenue
$171.9K
Gross Profit
$150.9K
Operating Profit
$-2.4M
Net Profit
$-2.4M
Gross Margin
87.8%
Operating Margin
-1403.9%
Net Margin
-1382.6%
YoY Growth
532.5%
EPS
$-0.12
Nexalin Technology, Inc. Q4 FY2025 Financial Summary
Nexalin Technology, Inc. reported revenue of $171.9K (up 532.5% YoY) for Q4 FY2025, with a net profit of $-2.4M (up 16.1% YoY) (-1382.6% margin). Cost of goods sold was $21.0K, operating expenses totaled $2.6M.
Key Financial Metrics
| Total Revenue | $171.9K |
|---|---|
| Net Profit | $-2.4M |
| Gross Margin | 87.8% |
| Operating Margin | -1403.9% |
| Report Period | Q4 FY2025 |
Nexalin Technology, Inc. Annual Revenue by Year
Nexalin Technology, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $301.6K).
Nexalin Technology, Inc. Quarterly Revenue & Net Profit History
Nexalin Technology, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $171.9K | +532.5% | $-2.4M | -1382.6% |
| Q3 FY2025 | $18.1K | -49.6% | $-2.3M | -12542.3% |
| Q2 FY2025 | $70.6K | +163.0% | $-1.6M | -2239.7% |
| Q1 FY2025 | $41.0K | -47.9% | $-2.0M | -4847.8% |
| Q4 FY2024 | $27.2K | +32.4% | N/A | N/A |
| Q3 FY2024 | $36.0K | +49.4% | $-2.4M | -6794.9% |
| Q2 FY2024 | $26.8K | -24.5% | $-1.3M | -4785.7% |
| Q1 FY2024 | $78.7K | +157.4% | $-1.0M | -1323.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $78671 | $26840 | $36031 | $27179 | $41015 | $70588 | $18149 | $171895 |
| YoY Growth | 157.4% | -24.5% | 49.4% | 32.4% | -47.9% | 163.0% | -49.6% | 532.5% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.8M | $1.6M | $5.3M | $4.2M | $2.9M | $6.6M | $5.1M | $4.6M |
| Liabilities | $507223 | $212104 | $299389 | $546694 | $574736 | $600584 | $357524 | $887333 |
| Equity | $2.3M | $1.4M | $5.0M | $3.7M | $2.3M | $6.0M | $4.8M | $3.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-763289 | $-1.2M | $-800210 | $-3.9M | $-1.4M | $-917165 | $-1.5M | $-1.1M |